DNA Repair Communiqué I
This first Communiqué in a series on DNA forms an introductory foundation,...
Read More
CLINUVEL Expands DNA Repair Program with 2nd DNA Repair Study
CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...
Read More
Appendix 4C & Activity Report
Melbourne, Australia, 31 January 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
SCENESSE® continued in Germany
CLINUVEL today announced that it has entered a second agreement with the...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 19 January 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Notification of Cessation of Securities
Melbourne, Australia, 19 January 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
CLINUVEL completes enrolment in world-first stroke study
CLINUVEL today announced that it has completed enrolment in its world-first study...
Read More
CLINUVEL’S GROWTH AND EXPANSION - H.C. Wainwright Bioconnect Conference 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read More